Table 1.

Characteristics of selected biomarkers for therapy monitoring in MIS-C.

Marker	Cut-off point	Sensitivity	Specificity	Likelihood ratio*
Comparison of acute MIS-C cases to remission (monitoring of therapy efficacy)
Early classical pathway activation marker C1s-C1-inhibitor complex	1795 ng/mL	91.18 77.04–96.95	90.91 76.43–96.86	10.029 (3.392–29.651)
Alternative pathway activation product Bb	1.11 ug/mL	96.77 83.81–99.83	93.94 80.39–98.92	15.968 (4.161–61.274)
Anaphylatoxin C3a	170 ng/mL	100 77.19–100	85.71 60.06–97.46	7.000 (1.940–25.255)
Terminal pathway activation product sC5b-9	363 ng/mL	79.4 63.20–89.65	75.76 58.98–87.17	3.276 (1.750–6.132)
Macrophage activation marker neopterin	10.7 nmol/L	100 88.65–100	100 89.57–100	inf (nan-inf)

*Likelihood ratio was calculated as sensitivity/(1-specificity), i.e. true positivity rate divided by the false positivity rate, indicating the diagnostic value of having a positive test result in supporting a certain condition (the remission of MIS-C).

For calculation of likelihood ratio positive result was considered in the following way: laboratory parameters below the cut-off were regarded as positive, as these values are supposed to indicate remission, which is the condition in question. Confidence intervals were calculated according to the method described by Simel et al⁴⁴.

nan not a number (cannot be calculated); inf infinity.